Intercept Pharmaceuticals (NASDAQ:ICPT) PT Raised to $26.00

Intercept Pharmaceuticals (NASDAQ:ICPT – Get Rating) had its price target lifted by stock analysts at Needham & Company LLC from $22.00 to $26.00 in a note issued to investors on Friday, Benzinga reports. The firm currently has a “buy” rating on the biopharmaceutical company’s stock. Needham & Company LLC’s price objective would indicate a potential upside of 25.73% from the stock’s previous close.

A number of other research analysts have also weighed in on the company. HC Wainwright cut their price objective on Intercept Pharmaceuticals from $16.00 to $14.00 and set a “neutral” rating on the stock in a report on Wednesday, November 16th. StockNews.com upgraded Intercept Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Thursday, November 3rd. Royal Bank of Canada upped their target price on Intercept Pharmaceuticals from $15.00 to $18.00 and gave the stock a “sector perform” rating in a research note on Wednesday, February 15th. Finally, Raymond James lowered their target price on Intercept Pharmaceuticals from $27.00 to $26.00 and set an “outperform” rating on the stock in a research note on Friday, January 20th. Four investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. Based on data from MarketBeat, Intercept Pharmaceuticals presently has a consensus rating of “Moderate Buy” and an average target price of $25.82.

Intercept Pharmaceuticals Stock Up 0.5 %

Shares of ICPT stock opened at $20.68 on Friday. The stock’s 50-day simple moving average is $17.40 and its 200-day simple moving average is $16.07. The company has a debt-to-equity ratio of 2.07, a quick ratio of 2.46 and a current ratio of 2.46. The firm has a market capitalization of $856.57 million, a PE ratio of 3.20 and a beta of 1.29. Intercept Pharmaceuticals has a fifty-two week low of $10.81 and a fifty-two week high of $21.86.

Institutional Trading of Intercept Pharmaceuticals

A number of hedge funds and other institutional investors have recently made changes to their positions in ICPT. JPMorgan Chase & Co. increased its position in shares of Intercept Pharmaceuticals by 53.7% during the first quarter. JPMorgan Chase & Co. now owns 305,441 shares of the biopharmaceutical company’s stock worth $4,970,000 after purchasing an additional 106,655 shares in the last quarter. Bank of New York Mellon Corp increased its position in shares of Intercept Pharmaceuticals by 2.6% during the first quarter. Bank of New York Mellon Corp now owns 105,729 shares of the biopharmaceutical company’s stock worth $1,720,000 after purchasing an additional 2,644 shares in the last quarter. MetLife Investment Management LLC increased its position in Intercept Pharmaceuticals by 46.9% in the 1st quarter. MetLife Investment Management LLC now owns 16,476 shares of the biopharmaceutical company’s stock valued at $268,000 after acquiring an additional 5,261 shares during the period. Vanguard Group Inc. increased its position in Intercept Pharmaceuticals by 21.2% in the 1st quarter. Vanguard Group Inc. now owns 2,389,249 shares of the biopharmaceutical company’s stock valued at $38,873,000 after acquiring an additional 417,490 shares during the period. Finally, Fuller & Thaler Asset Management Inc. increased its position in Intercept Pharmaceuticals by 0.5% in the 1st quarter. Fuller & Thaler Asset Management Inc. now owns 164,210 shares of the biopharmaceutical company’s stock valued at $2,672,000 after acquiring an additional 825 shares during the period. Institutional investors and hedge funds own 81.09% of the company’s stock.

About Intercept Pharmaceuticals

(Get Rating)

Intercept Pharmaceuticals, Inc operates as a biopharmaceutical company. The firm engages in the research, development, and commercialization of novel therapeutics in treating chronic liver diseases. Its product pipeline includes OCALIVA, which is used for the treatment of biliary cholangitis, nonalcoholic steatohepatitis, sclerosing cholangitis and biliary atresia.